The anti-telomerase compound Imetelstat or GRN163L, which has been used clinically, was not very effective, especially in solid tumors, and also caused significant hematologic toxicity.10 Moreover, inhibiting TERT is also detrimental to normal stem and germline cells, leading to challenges for telomerase-targeted therapy in the clinic.11 Importantly, however, recent studies have shown that GA-binding protein transcription factor subunit beta 1 (GABPB1) is a tumor-specific TERT transcription factor. Here, TERT is linked to neoplasm.